Clinical Trials - Lectures

Analytical Validation of the MPACT Assay, a Targeted Next Generation Sequencing Clinical Assay for Cancer Patient Treatment Selection

Progress and Implications of Novel Technology for Clinical Trials

Clinical reporting of NGS data

Progress and Implications of Novel Technology for Clinical Trials

Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients

Biology-Driven Clinical Trials

Molecular Profiling based Assignment of Cancer Therapy

Biology-Driven Clinical Trials

Rationale of the Design of the SHIVA trial

Biology-Driven Clinical Trials

Rationale of the Design of the I-SPY trial

Biology-Driven Clinical Trials

Rationale of the Design of the WINTHER Trial

Biology-Driven Clinical Trials

Two-Stage adaptive cutoff design for building and validating a prognostic biomarker signature

New Trial Concepts and Challenges for the Future

Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)

Proffered Paper Session

Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors

Proffered Paper Session

Introducing Genomics into Clinical Trials

Next Generation Gene Sequencing: how to use?

A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors

Proffered Paper Session

Pursuing Molecular Stratification in Phase I Trials

Challenges in Phase I

The Challenges of Drug Combination Studies

Challenges in Phase I

Is There an Optimal Biological Dose?

Challenges in Phase I

Enrichment Strategies for Patient Selection in 6 Early Oncology Trials – a Missed Opportunity, a Must or a way to Focus on the Wrong Target?

Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?

Incorporating Biomarkers Into Phase 2 Trials – 5 Multiple Options, Multiple Challenges

Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?

Response-Adaptive Randomized Early Clinical Trials – can BATTLE and SPYs help in co- development of cancer drugs and diagnostics?

Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?

The need for new concepts in clinical trials: The role of NOCI & the MINDACT example

Integrating Biology in Novel Clinical Trials